NCT07095452View on ClinicalTrials.gov

A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

PHASE2/PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

660

Participants

Timeline

Start Date

November 12, 2025

Primary Completion Date

January 31, 2042

Study Completion Date

January 31, 2042

Conditions
Multiple Myeloma
Interventions
DRUG

Etentamig

Intravenous (IV) Infusion

DRUG

Lenalidomide

Oral Capsule

DRUG

Daratumumab

Subcutaneous Injection

DRUG

Dexamethasone

Oral Tablet

DRUG

Dexamethasone

IV Injection

Sponsors

Lead Sponsor

AbbVie
All Listed Sponsors
collaborator

IFM (Intergroupe Français du Myélome)

UNKNOWN

collaborator

PETHEMA (Program for the Study and Treatment of Haematological Malignances)

UNKNOWN

lead

AbbVie

INDUSTRY